Glucagon-Like Peptide-1 Receptor
"Glucagon-Like Peptide-1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).
Descriptor ID |
D000067757
|
MeSH Number(s) |
D12.776.543.750.695.021.500 D12.776.543.750.750.360.100.500
|
Concept/Terms |
Glucagon-Like Peptide-1 Receptor- Glucagon-Like Peptide-1 Receptor
- Glucagon Like Peptide 1 Receptor
- Peptide-1 Receptor, Glucagon-Like
- Receptor, Glucagon-Like Peptide-1
- GLP-1R Receptor
- GLP 1R Receptor
- Receptor, GLP-1R
- GLP1R Protein
- Protein, GLP1R
- GLP-1 Receptor
- GLP 1 Receptor
- Receptor, GLP-1
- GLP1R Receptor
- Receptor, GLP1R
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-1 Receptor".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-1 Receptor".
This graph shows the total number of publications written about "Glucagon-Like Peptide-1 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-1 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2001 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2011 | 0 | 2 | 2 |
2012 | 0 | 2 | 2 |
2013 | 0 | 1 | 1 |
2014 | 0 | 2 | 2 |
2015 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2018 | 2 | 0 | 2 |
2019 | 3 | 1 | 4 |
2020 | 0 | 1 | 1 |
2021 | 0 | 4 | 4 |
2022 | 1 | 5 | 6 |
2024 | 5 | 3 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptide-1 Receptor" by people in Profiles.
-
GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. JAMA Intern Med. 2024 Nov 01; 184(11):1314-1323.
-
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes. J Am Coll Cardiol. 2024 Aug 20; 84(8):696-708.
-
Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2024 Jul 25; 391(4):371-372.
-
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity? Curr Cardiol Rep. 2024 Sep; 26(9):1011-1019.
-
Dipeptidyl peptidase 4 inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide 1 receptor agonists do not worsen diabetic macular edema. J Diabetes Complications. 2024 Aug; 38(8):108808.
-
Management of Type 2 Diabetes Mellitus With Noninsulin Pharmacotherapy. Am Fam Physician. 2024 04; 109(4):333-342.
-
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression. Curr Opin Nephrol Hypertens. 2024 05 01; 33(3):331-336.
-
The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. Clin Gastroenterol Hepatol. 2024 Aug; 22(8):1565-1574.
-
Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024 01; 23(1):37-45.
-
Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med. 2022 09 22; 387(12):1063-1074.